History of severe hypersensitivity reaction to monoclonal antibodies.
History of severe hypersensitivity reactions to other mAbs
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
A history of hypersensitivity to other humanized monoclonal antibodies.
History of severe hypersensitivity reactions to other monoclonal antibodies.
Patient has history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).
Severe hypersensitivity to other monoclonal antibodies (mAbs).
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reactions to monoclonal antibodies.
Hypersensitivity to any of the inactive ingredients (histidine, sucrose, polysorbate 80) or to other humanized monoclonal antibodies (mAbs)
No history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of grade >= 3 allergy to human monoclonal antibodies
Monoclonal antibodies therapy within 2 weeks before study entry
History of severe allergic reactions to humanized monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies
Severe hypersensitivity reactions to monoclonal antibodies, known hypersensitivity to the investigational medicinal products or to one or more of the excipients, autoimmune diseases (inflammatory bowel diseases, interstitial lung disease, or pulmonary fibrosis), and live vaccines within 28 days prior to study entry.
History of severe hypersensitivity reactions to other monoclonal antibodies
Known prior hypersensitivity to the investigational product or any component formulations, including known severe hypersensitivity reactions to monoclonal antibodies
History of sensitivity or allergy to monoclonal antibodies (mAbs) or immunoglobulin G (IgG)
No history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
Allergy to murine-based monoclonal antibodies
Prior hypersensitivity to monoclonal antibodies
Monoclonal antibodies therapy within 2 weeks before study entry
History of grade 3 or higher allergy to humanized monoclonal antibodies
History of severe allergic reactions to humanized monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal Antibodies
History of grade 3 or above hypersensitivity reactions to other monoclonal antibodies
Patients with history of hypersensitivity to monoclonal antibodies
History of sensitivity or allergy to monoclonal antibodies or immunoglobulin G
Patients who have experienced allergic reactions to monoclonal antibodies
History of severe hypersensitivity reactions to other mAbs
History of severe hypersensitivity reaction to other monoclonal antibodies
No known hypersensitivity to rat monoclonal antibodies
Monoclonal antibodies therapy within 2 weeks before study entry
No history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of severe hypersensitivity reactions to other mAbs
History of severe hypersensitivity to monoclonal antibodies (mAbs).
History of severe hypersensitivity reactions to other monoclonal antibodies.
Patients with known hypersensitivity to any of the components of MCLA-117 or who have had prior hypersensitivity reactions to human or humanized monoclonal antibodies;
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).
Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.
History of severe hypersensitivity reaction with biologics therapy (monoclonal antibodies)
Known hypersensitivity to monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies which in the opinion of the investigator may pose an increased risk of a serious infusion reaction.
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of severe hypersensitivity reactions to other monoclonal antibodies.
History of severe hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigator
For Combination Dose Finding and Combination Expansion cohorts only: history of hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the lead principal investigator (PI)
History of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies, nivolumab or related compounds
History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of severe hypersensitivity reactions to other mAbs.
A history of allergy to human monoclonal antibodies.
History of grade 3 or higher hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigator
Subject has a known hypersensitivity to monoclonal antibodies or to agents of similar biologic composition as IMC-CS4.
History of severe hypersensitivity reactions to other biologic drugs or monoclonal antibodies
Known severe hypersensitivity reactions to monoclonal antibodies (Grade ?3), any history of anaphylaxis.
History of severe hypersensitivity reactions to other monoclonal antibodies
Hypersensitivities to other monoclonal antibodies;
Known hypersensitivity to any of the components of MM-302 or who have had hypersensitivity reactions to fully human monoclonal antibodies
Monoclonal antibodies within 28 days
History of severe hypersensitivity reactions or immune related adverse events to other monoclonal antibodies
Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.
Prior hypersensitivity to monoclonal antibodies
History of Grade ? 3 allergy to human monoclonal antibodies.
History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (e.g. monoclonal antibodies, polyclonal gamma globulin, polysorbates)
History of allergic reactions to monoclonal antibodies
History of severe hypersensitivity reactions to other mAbs.
History of severe hypersensitivity to monoclonal antibodies.
History of severe hypersensitivity to monoclonal antibodies or to the chemotherapies under investigation including any ingredient used in the formulation.
History of severe hypersensitivity reactions to other monoclonal antibodies.
History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
Known allergy or hypersensitivity to monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies.
History of severe hypersensitivity reaction to other monoclonal antibodies